In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria | Zendy

David M. Livermore | Zendy; Shazad Mushtaq | Zendy; Marina Warner | Zendy; Anna Vickers | Zendy; Neil Woodford | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

Author(s) -

David M. Livermore,

Shazad Mushtaq,

Marina Warner,

Anna Vickers,

Neil Woodford

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw593

Subject(s) - cefepime , citrobacter , microbiology and biotechnology , enterobacter , enterobacteriaceae , acinetobacter baumannii , stenotrophomonas maltophilia , klebsiella pneumoniae , acinetobacter , biology , agar dilution , pseudomonas aeruginosa , escherichia coli , antimicrobial , minimum inhibitory concentration , bacteria , imipenem , antibiotics , antibiotic resistance , biochemistry , genetics , gene

Diazabicyclooctanes (DBOs) inhibit class A, class C and some class D β-lactamases. A few also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent 'enhancer' effect, potentiating β-lactams targeting PBP3. We tested a novel DBO, zidebactam, combined with cefepime.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research